irinotecan hydrochloride

FDA Drug Profile — Camptosar, Irinotecan Hydrochloride

irinotecan hydrochloride is listed in the FDA National Drug Code directory with 4 NDC codes, marketed under brand names including Camptosar, Irinotecan Hydrochloride. Available dosage form: injection, solution.

Drug details

Generic Name
irinotecan hydrochloride
Brand Names
Camptosar, Irinotecan Hydrochloride
Application Number
NDA020571
Sponsor
Pharmacia & Upjohn Company LLC
NDC Codes
4
Dosage Forms
INJECTION, SOLUTION
Routes
INTRAVENOUS
Active Ingredients
IRINOTECAN HYDROCHLORIDE

Indications and Usage

1 INDICATIONS AND USAGE • CAMPTOSAR is indicated as a component of first-line therapy in combination with 5-fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic carcinoma of the colon or rectum. • CAMPTOSAR is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. CAMPTOSAR is a topoisomerase inhibitor indicated for: • First-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum. ( 1 ) • Patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. ( 1 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.